MILLENNIUM MANAGEMENT LLC
Position in MRVI — Maravai Lifesciences Holdings, Inc.
CIK 1273087
NEW YORK, NY
Position in MRVI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$40,611,292
+$35,943,236 QoQ
Shares Held
6,508,220
+294.6% QoQ
Ownership
2.51%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#5
of 177 holders
Holding Since
Dec 2020
23 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MRVI Over Time
Shares Held
Position Value (USD)
Derivatives in MRVI
reported options exposure · as of Mar 31, 2024CallValue
$520,200
CallShares
60,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026MILLENNIUM MANAGEMENT LLC holds $4,596,585,112 across 322 Biotechnology names. MRVI ranks #24 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
468,410 | $232,673,299 | |
| 2 | INSM |
INSMED Inc
|
2,048,005 | $218,358,293 | |
| 3 | APGE |
Apogee Therapeutics, Inc.
|
1,491,404 | $197,954,052 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
763,880 | $184,072,163 | |
| 5 | ONC |
BeOne Medicines Ltd.
|
543,323 | $154,830,755 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
556,088 | $136,113,659 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
2,071,816 | $118,549,311 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
165,120 | $102,958,924 |
All Filings in MRVI
Export CSV
33 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $40,611,292 | 6,508,220 | Shares | Sole | 2026-08-14 | |
| 2026-06-23 | $37,054,385 | 6,900,258 | Shares | Sole | 2026-06-29 | |
| 2026-06-16 | $36,690,835 | 7,323,520 | Shares | Sole | 2026-06-23 | |
| 2026-05-06 | $28,481,724 | 7,228,864 | Shares | Sole | 2026-05-12 | |
| 2026-03-31 | $4,668,056 | 1,649,490 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $5,840,419 | 1,797,052 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,261,947 | 439,703 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $597,889 | 248,087 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $3,042,553 | 1,376,721 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $10,394,572 | 1,907,261 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $35,943,342 | 4,325,312 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $42,735,118 | 5,968,592 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $45,560,442 | 5,254,953 | Shares | Sole | 2024-05-15 | |
| 2024-03-31 | $520,200 | 60,000 | Call | Sole | 2024-05-15 | |
| 2023-12-31 | $37,903,860 | 5,786,849 | Shares | Sole | 2024-02-14 | |
| 2023-12-31 | $1,442,965 | 220,300 | Call | Sole | 2024-02-14 | |
| 2023-09-30 | $42,621,990 | 4,262,199 | Shares | Sole | 2023-11-14 | |
| 2023-09-30 | $1,200,000 | 120,000 | Call | Sole | 2023-11-14 | |
| 2023-06-30 | $1,180,850 | 95,000 | Call | Sole | 2023-08-14 | |
| 2023-06-30 | $2,752,163 | 221,413 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $145,605 | 10,393 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $429,300 | 30,000 | Call | Sole | 2023-02-14 | |
| 2022-12-31 | $37,142,291 | 2,595,548 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $45,858,875 | 1,796,274 | Shares | Sole | 2022-11-14 | |
| 2022-09-30 | $2,394,714 | 93,800 | Call | Sole | 2022-11-14 | |
| 2022-06-30 | $3,103,877 | 109,253 | Shares | Sole | 2022-08-15 | |
| 2022-06-30 | $2,272,800 | 80,000 | Call | Sole | 2022-08-15 | |
| 2022-03-31 | $23,443,228 | 664,679 | Shares | Sole | 2022-05-16 | |
| 2021-12-31 | $21,855,836 | 521,619 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $18,589,050 | 378,750 | Shares | Sole | 2021-11-15 | |
| 2021-06-30 | $15,801,064 | 378,650 | Shares | Sole | 2021-08-16 | |
| 2021-03-31 | $13,030,162 | 365,605 | Shares | Sole | 2021-05-17 | |
| 2020-12-31 | $19,794,828 | 705,698 | Shares | Sole | 2021-02-16 | |
| No filing history on record for this holder in this stock. | ||||||